Endometriosis | A Drug Pipeline Analysis Report 2018 | Technavio
Aug. 09, 2018
LONDON--(BUSINESS WIRE)--Aug 9, 2018--Technavio has announced their latest pipeline analysis report on the drug pipeline for . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat endometriosis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180809005651/en/
Technavio has published a new report on the drug development pipeline for endometriosis, including a detailed study of the pipeline molecules. (Photo: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
Endometriosis: Market overview
Endometriosis is a condition in which cells similar to the cells in the endometrium (tissue layer that normally covers the inner part of the uterus) grow outside the uterus. Endometriosis is not followed by any symptoms, but sometimes, it leads to painful menstruation, lower abdominal pain, or pain during sexual intercourse. It can also lead to infertility.
According to a senior market research analyst at Technavio, “The main areas where endometriosis occurs are within the fallopian tubes, outside the fallopian tubes and ovaries, the outer surface of the uterus and intestines, and on the surface of the pelvic cavity. It is very rarely found on the surface of the liver, old scars, lungs, or the brain.”
Endometriosis: Segmentation analysis
This pipeline analysis report segments the endometriosis market based on therapies employed (monotherapy and combination therapy), RoA (oral, intramuscular, intravaginal, and subcutaneous), therapeutic modality (small molecule, peptide, fusion protein, monoclonal antibody and vaccine), targets (GnRH receptor, AKR1C3, P2X3R, progesterone receptor, and others), MoA (GnRH receptor agonist, AKR1C3 inhibitor, P2X3R antagonist, and others), geographical segmentation (Japan, Italy, Hungary, The Czech Republic, US, Poland, and others) and recruitment status (active, not recruiting, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, around 46% of the molecules that are being investigated for the treatment of endometriosis are small molecules. These molecules are chemically manufactured active substances that enter cells easily due to their low molecular weight.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180809005651/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: WOMEN HEALTH CONSUMER GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 08/09/2018 01:44 PM/DISC: 08/09/2018 01:44 PM